Stock 4534 MOCHIDA PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Mochida Pharmaceutical Co., Ltd.

Equities

4534

JP3922800002

Market Closed - Japan Exchange
Other stock markets
 02:00:00 2024-05-02 am EDT 		5-day change 1st Jan Change
3,190 JPY -0.47% Intraday chart for Mochida Pharmaceutical Co., Ltd. +1.43% -2.45%
Apr. 25 Hidehiro Imatsu named president of Goldman Sachs Japan RE
Mar. 21 Tranche Update on Mochida Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 15, 2023. CI

Strengths

  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.49 for the 2024 fiscal year.
  • The company appears to be poorly valued given its net asset value.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company benefits from high valuations in earnings multiples.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last few months, analysts have been revising downwards their earnings forecast.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
MOCHIDA PHARMACEUTICAL CO., LTD. Stock Mochida Pharmaceutical Co., Ltd.
-2.45% 740M -
NOVO NORDISK A/S Stock Novo Nordisk A/S
+21.85% 546B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.77% 359B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.97% 323B
B-
ABBVIE INC. Stock AbbVie Inc.
+5.69% 290B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.68% 234B
B+
NOVARTIS AG Stock Novartis AG
+3.65% 198B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-11.12% 194B
A+
AMGEN INC. Stock Amgen Inc.
+8.08% 167B
C+
PFIZER, INC. Stock Pfizer, Inc.
-3.40% 157B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 4534 Stock
  4. Ratings Mochida Pharmaceutical Co., Ltd.